Search Result

Search Result

Isoforms Recommended:	CLK

Results for "

CLK2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Autophagy (1) Casein Kinase (1) CDK (17) DYRK (10) GSK-3 (3) IRAK (1) MELK (2) mTOR (2) Pim (2) RIP kinase (2) Small Interfering RNA (siRNA) (1) SRPK (1) TNF Receptor (1) Wnt (1)
By Research Areas:	Cancer (16) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (1)

21

Inhibitors & Agonists

1

Peptides

1

Recombinant Proteins

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

Ipivivint	CDK Wnt	Cancer
Ipivivint (compound 38) is a potent CDC-like kinase (CLK) inhibitor with EC₅₀s of 1 nM, 7 nM for CLK2 and CLK3, respectively. Ipivivint inhibits Wnt pathway (EC₅₀=13 nM) .

DB18	CDK	Cancer
DB18 is a potent and selective inhibitor of **CDC2-like kinases (CLKs), with IC₅₀** values in the range of 10-30 nM for CLK1, CLK2 and CLK4. DB18 has anti-tumor activity .

CC-671 1 Publications Verification	CDK	Cancer
CC-671 is a dual TTK protein kinase/CDC2-like kinase (CLK2) inhibitor with IC₅₀s of 0.005 and 0.006 μM for TTK and CLK2, respectively.

CLK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CLK2 Human Pre-designed siRNA Set A contains three designed siRNAs for CLK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CLK2 Human Pre-designed siRNA Set A CLK2 Human Pre-designed siRNA Set A

KuWal151	CDK DYRK	Cancer
KuWal151 is a CLK1, CLK2 and CLK4 inhibitor with a high selectivity margin towards DYRK kinases. KuWal151 has potent antiproliferative activity in an array of cultured cancer cell lines .

CK2 inhibitor 2	Casein Kinase	Cancer
CK2 inhibitor 2 is a potent, selective and orally active inhibitor of *CK2, with an IC₅₀* of 0.66 nM. CK2 inhibitor 2 shows high selectivity for Clk2 (IC₅₀=32.69 nM)/CK2. CK2 inhibitor 2 exhibits favorable antiproliferative and antitumor activity .

HY-123600

SRI-29329

CDK Others

SRI-29329 is a specific CLK inhibitor, with IC₅₀ values of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively .
HY-162398

LQ23

CDK Inflammation/Immunology

LQ23 is a selective inhibitor for CDC2-like kinase 2 (CLK2) with an IC₅₀ of 1.4 nM. LQ23 exhibits anti-inflammatory activity .

CLK1/2-IN-3	CDK SRPK	Cancer
LK1/2-IN-3 (compound 3) is a potent and selective *CLK1* and *CLK2* inhibitor with IC₅₀ values of 1.1, 2.1, 130, 260, 260 nM for CLK1, CLK2, SRPK1, SRPK2, SRPK3, respectively. CLK1/2-IN-3 shows anti-proliferative activity. CLK1/2-IN-3 reduces the levels of endogenous phosphorylated SR proteins and increases the expression of S6K mRNAs .

HY-113825

CLK1/2-IN-1

CDK Cancer

CLK1/2-IN-2 is CLK1 and CLK2 inhibitor with IC₅₀ values of 16 nM and 45 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities ^{[1] ^.}
HY-113670

CLK1/2-IN-2

CDK Cancer

CLK1/2-IN-2 is CLK1 and CLK2 inhibitor with IC₅₀ values of 1.1 nM and 2.4 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities ^{[1] ^.}

ML167 CID44968231; NCGC00188654	CDK DYRK	Cancer
ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor with IC₅₀ of 136 nM, >10-fold selectivity for closely related kinases Clk1, Clk2, Clk3 and Dyrk1A/1B .

CLK-IN-T3 1 Publications Verification	CDK DYRK	Cancer
CLK-IN-T3 is a high potent, selective, and stable CDC-like kinase (CLK) inhibitor with IC₅₀s of 0.67 nM, 15 nM, and 110 nM for CLK1, CLK2, and CLK3 protein kinases, respectively. CLK-IN-T3 has anti-cancer activity .

HTH-01-091	MELK DYRK Pim mTOR CDK GSK-3 RIP kinase	Cancer
HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC₅₀ of 10.5 nM. HTH-01-091 also inhibits *PIM1/2/3, RIPK2, DYRK3, smMLCK* and *CLK2*. HTH-01-091 can be uesd for breast cancer research .

Dyrk1A-IN-7	DYRK	Metabolic Disease Inflammation/Immunology Cancer
Dyrk1a-in-7 (Compound 29) is a selective DYRK1A kinase inhibitor, and has good kinase selectivity for CLK1 kinase. The IC₅₀ value of DYRK1A is 28 nM. For CLK2, K_d is 17.5 nM. Dyrk1a-in-7 can be used in the research of cancer, type Ⅱ diabetes and neurological diseases .

HTH-01-091 TFA	MELK DYRK Pim mTOR CDK GSK-3 RIP kinase	Cancer
HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC₅₀ of 10.5 nM. HTH-01-091 TFA also inhibits *PIM1/2/3, RIPK2, DYRK3, smMLCK* and *CLK2*. HTH-01-091 TFA can be uesd for breast cancer research .

EHT 5372	DYRK CDK GSK-3	Neurological Disease Metabolic Disease Cancer
EHT 5372 is a highly potent and selective inhibitor of DYRK's family kinases with IC₅₀s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, and 221 nM for DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK4, GSK-3α, and GSK-3β, respectively ^[2].

Leucettinib-92	CDK DYRK	Others
Leucettinib-92 (compound 92) is an inhibitor of DYRK/CLK kinase, The IC₅₀s are 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM (CLK3), 124 nM (DYRK1A), 204 nM (DYRK1B), 0.16 μM (DYRK2), respectively. 1.0 μM (DYRK3), 0.52 μM (DYRK4), 2.78 μM (GSK3) .

CLK1-IN-3	CDK DYRK Autophagy	Cancer
CLK1-IN-3 (compound 10ad) is a potent and selective *Clk1* inhibitor, with an IC₅₀ of 5 nM and over 300-fold selectivity for Dyrk1A. CLK1-IN-3 also shows a relatively potent inhibition against *Clk2* and *Clk4, with IC₅₀* values of 42 and 108 nM, respectively. CLK1-IN-3 potently induces autophagy in vitro. CLK1-IN-3 can be used for acute liver injury (ALI) research .

HS-276	IRAK TNF Receptor	Inflammation/Immunology
HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a K_i of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC₅₀ values of 8.25, 29, 33, 63, 125, 264, 270, 810, 1280, and 5585 nM, respectively. HS-276 can be used for rheumatoid arthritis (RA) research .

T025 2 Publications Verification	CDK Apoptosis DYRK	Cancer
T025 is an orally active and highly potent inhibitor of **Cdc2-like kinase (CLKs)*, with K_d values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC₅₀* values: 30-300 nM). T025 has an anti-tumor efficiency, mainly for MYC-driven disease research .

Cat. No.	Compare	Product Name	Species	Source

	CLK2 Protein, Human (GST) CLK2; Dual specificity protein kinase CLK2; CDC-like kinase 2	Human	E. coli
	The CLK2 protein is a dual-specificity kinase that phosphorylates serine- and arginine-rich (SR) proteins in the spliceosome complex. CLK2 Protein, Human (GST) is the recombinant human-derived CLK2 protein, expressed by E. coli , with N-GST labeled tag. The total length of CLK2 Protein, Human (GST) is 367 a.a., .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MedChemExpress Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator

Subscribe to our E-newsletter

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2024 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us